scholarly journals MP19-13 COMPARING UROLOGIST RECOMMENDATIONS FOR SMALL RENAL MASS BIOPSY WITH PATIENT OPINIONS BEFORE AND AFTER COUNSELING

2019 ◽  
Vol 201 (Supplement 4) ◽  
Author(s):  
Tariq A. Khemees* ◽  
Anthony Bui ◽  
Daniel D. Shapiro ◽  
Sara L. Best ◽  
Shane A. Wells ◽  
...  
2015 ◽  
Vol 2 (4) ◽  
pp. 174-186 ◽  
Author(s):  
Brunolf Walther Lagerveld ◽  
Ferida Sivro ◽  
Johan A. Van der Zee ◽  
Phillippe C Baars

The aim of this study was to describe the characteristics of positron emission tomography (PET) molecular imaging combined with low-dose computed tomography (CT) in small renal mass (SRM) treated with cryoablation (CA). Currently, treatment success is defined by the absence of contrast enhancement at CT. However, the use of contrast is relatively contraindicated in patients with renal function impairment, mandating alternative follow-up strategies. Several reasons were identified as criteria for performing PET-CT before and/or after SRM-CA in 9 patients, and the results were retrospectively studied. The histology revealed renal cell carcinoma in 7 patients andoncocytoma in 2 patients. In 6 patients, a PET-CT was performed before and after CA. In one patient, the PET-CT was performed only before CA and in 2 patients only after CA. Before CA, clearly there was metabolic uptake of fluorine-18 fluorodeoxyglucose (18F-FDG) in the SRM in all patients. Following CA, the absence of 18F-FDG uptakes in the SRM could clearly be noticed. However, the tracer cannot always be distinguished from focal recurrence or reactive inflammatory tissue. In one patient, asymptomatic metastatic bone lesions were noticed when performing PET-CT at follow-up. This pilot study with 18F-FDG PET-CT for the follow-up of SRM cryosurgery showed that 18F-FDG PET-CT imaging could be used to characterize cryoablative tissue injury at different times after CA.


2014 ◽  
Vol 113 (6) ◽  
pp. 854-863 ◽  
Author(s):  
Matvey Tsivian ◽  
Edward N. Rampersaud ◽  
Maria del Pilar Laguna Pes ◽  
Steven Joniau ◽  
Raymond J. Leveillee ◽  
...  

2016 ◽  
Vol 14 (3) ◽  
pp. 226-230 ◽  
Author(s):  
Madhur Nayan ◽  
Patrick O. Richard ◽  
Michael A.S. Jewett ◽  
John R. Kachura ◽  
Andrew Evans ◽  
...  

2020 ◽  
Vol 20 ◽  
pp. S17
Author(s):  
O.E. Lynch ◽  
S. Considine ◽  
N. O’Dwyer ◽  
U. Haroon ◽  
T. Crotty ◽  
...  

2020 ◽  
Vol 34 (1) ◽  
pp. 99-106 ◽  
Author(s):  
Mohammed Shahait ◽  
Stephen Jackman ◽  
Jaime Landman ◽  
Eric Lechevallier ◽  
Ignace Billiet ◽  
...  

2017 ◽  
Vol 197 (4S) ◽  
Author(s):  
Amy H. Lim ◽  
Maria Rozo ◽  
Sara L Best ◽  
Shane A Wells ◽  
Meghan G Lubner ◽  
...  

Author(s):  
Sapan N. Ambani ◽  
James Stuart Wolf

2020 ◽  
Vol 16 (1) ◽  
pp. 1-4
Author(s):  
Md Jahangir Kabir

Abstract Not Available Bangladesh Journal of Urology, Vol. 16, No. 1, Jan 2013 p.1-4


2020 ◽  
Vol 7 (3) ◽  
pp. 20-25
Author(s):  
Lauren Nahouraii ◽  
Jordan Allen ◽  
Suzanne Merrill ◽  
Erik Lehman ◽  
Matthew Kaag ◽  
...  

Pathologic characteristics of extirpated renal cell carcinoma (RCC) specimens <7  cm were reviewed to get better information on technical nuances of renal mass biopsy (RMB). Specimens were stratified according to tumor stage, nuclear grade, size, histology, presence of lymphovas-cular invasion (LVI), necrosis, and sarcomatoid features. When considering pT1 (0–7 cm) tumors pT1b (4–7 cm), RCC masses were more likely to have necrosis (43% vs 16%, P < 0.001), LVI (6% vs 2%, P = 0.024), high-grade nuclear elements (29% vs 17%, P < 0.001), and sarcomatoid features (2% vs 0%, P = 0.006) compared with pT1a (0–4 cm) tumors. Additionally, pT3a tumors were more highly associated with necrosis (P = 0.005), LVI, sarcomatoid features, and high-grade disease (P for all < 0.001) when compared to pT1 masses. For masses <4 cm, pT3a cancers were more likely to demonstrate necrosis (38% vs 16%, P < 0.001), LVI (10% vs 2%, P = 0.037), high-grade nuclear elements (31% vs 17%, P = 0.05), and sarcomatoid features (3% vs 0%, P = 0.065) compared to pT1a tumors. Similarly, for masses 4–7 cm, pathologic T3a tumors were significantly more likely to have sarcomatoid features (16% vs 2%, P < 0.001) and LVI (28% vs 6%, P < 0.001) compared to pT1b tumors. In summary, pT3a tumors and those RCC masses >4 cm exhibit considerable histologic heterogeneity and may harbor elements that are not easily appreciated with limited renal sampling. Therefore, if RMB is considered for renal masses greater than 4 cm or those that abut sinus fat, a multi-quadrant biopsy approach is necessary to ensure adequate sampling and characterization of the mass.


Sign in / Sign up

Export Citation Format

Share Document